Welcome

As a person affected by RVO, you know that your vision is precious, but do you know how to protect it?
 

Here, you’ll learn a lot about retinal vein occlusion and the benefit of anti-VEGF treatments. Empower yourself to take an active role in saving your vision. Use these resources to take part in your care today—for yourself and for your loved ones.
 

Social Media

Let’s raise awareness about this disease, which affects so many lives. Join our supportive online communities, part of our System ENABLE™, and become an advocate for all who are touched by CRVO.

 

Other Resources

Clinical Trial Resources:
 
ClinicalTrials.gov
A service of the U.S. National Institutes of Health – ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. 
 
 

References

1. Figueroa MS, Contreras, I. “Potential Anti-Vascular Endothelial Growth Factor Therapies for Central Retinal Vein Occlusion.” Drugs. 2012;72(16):2063-2071.
 

2. McAllister, IL. Central retinal vein occlusion: a review. Clinical and Experimental Ophthalmology. 2012;40:48-58.
 

3. Figueroa MS, Contreras, I. “Potential Anti-Vascular Endothelial Growth Factor Therapies for Central Retinal Vein Occlusion.” Drugs. 2012;72(16):2063-2071.
 

4. “Leading Causes of Blindness in the U.S.” National Eye Institute, National Institutes of Health. Accessed June 2013, http://www.nei.nih.gov/health/fact_sheet.asp.
 

6. Figueroa MS, Contreras, I. “Potential Anti-Vascular Endothelial Growth Factor Therapies for Central Retinal Vein Occlusion.” Drugs. 2012;72(16):2063-2071.
 

7. “Visual Acuity: What is 20/20 Vision?” aoa.org. American Optometric Association. Accessed June 2013, http://www.aoa.org/patients-and-public/eye-and-vision-problems/glossary-of-eye-and-vision-conditions/visual-acuity.
 

8. Kiire CA, Chong NV. Managing retinal vein occlusion. BMJ. 2012;344(e499):1-16.
 

9. McIntosh RL, Rogers SL, Lim L, et al. Natural History of Central Retinal Vein Occlusion: An Evidence-Based Systematic Review. Ophthalmology. June 2010;117(6):1113-1123.e15.
 

10. Laouri M, Chen E, Looman M, Gallagher M. The burden of disease of retinal vein occlusion: review of the literature. Eye. 2011;25:981-988.
 

11. McAllister, IL. Central retinal vein occlusion: a review. Clinical and Experimental Ophthalmology. 2012;40:48-58.
 

12. Kiire CA, Chong NV. Managing retinal vein occlusion. BMJ. 2012;344(e499):1-16.
 

13. Remington, Lee Ann. Clinical Anatomy of the Visual System, Second Edition. Elsevier Inc., 2005. Print.
 

14. Remington, Lee Ann. Clinical Anatomy of the Visual System, Second Edition. Elsevier Inc., 2005. Print.
 

15. Remington, Lee Ann. Clinical Anatomy of the Visual System, Second Edition. Elsevier Inc., 2005. Print.
 

16. Remington, Lee Ann. Clinical Anatomy of the Visual System, Second Edition. Elsevier Inc., 2005. Print.
 

17. Remington, Lee Ann. Clinical Anatomy of the Visual System, Second Edition. Elsevier Inc., 2005. Print.
 

18. “Retinal vein occlusion.” MedlinePlus. U.S. National Library of Medicine, 15 Aug 2014. Web. 5 Sept 2014. http://www.nlm.nih.gov/medlineplus/ency/article/007330.htm
 

19. Remington, Lee Ann. Clinical Anatomy of the Visual System, Second Edition. Elsevier Inc., 2005. Print.
 

20. Remington, Lee Ann. Clinical Anatomy of the Visual System, Second Edition. Elsevier Inc., 2005. Print.
 

21. Remington, Lee Ann. Clinical Anatomy of the Visual System, Second Edition. Elsevier Inc., 2005. Print.
 

22. Kiire CA, Chong NV. Managing retinal vein occlusion. BMJ. 2012;344(e499):1-16.
 

23. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

24. McAllister, IL. Central retinal vein occlusion: a review. Clinical and Experimental Ophthalmology. 2012;40:48-58.
 

25. Spina C, Benedetto U, Parodi MB, et al. Practical Management of Retinal Vein Occlusions. Ophthalmol Ther. 2012;1(3):1-10.
 

26. Laouri M, Chen E, Looman M, Gallagher M. The burden of disease of retinal vein occlusion: review of the literature. Eye. 2011;25:981-988.
 

27. Spina C, Benedetto U, Parodi MB, et al. Practical Management of Retinal Vein Occlusions. Ophthalmol Ther. 2012;1(3):1-10.
 

28. McAllister, IL. Central retinal vein occlusion: a review. Clinical and Experimental Ophthalmology. 2012;40:48-58.
 

29. Spina C, Benedetto U, Parodi MB, et al. Practical Management of Retinal Vein Occlusions. Ophthalmol Ther. 2012;1(3):1-10.
 

30. Laouri M, Chen E, Looman M, Gallagher M. The burden of disease of retinal vein occlusion: review of the literature. Eye. 2011;25:981-988.
 

31. Spina C, Benedetto U, Parodi MB, et al. Practical Management of Retinal Vein Occlusions. Ophthalmol Ther. 2012;1(3):1-10.
 

32. Laouri M, Chen E, Looman M, Gallagher M. The burden of disease of retinal vein occlusion: review of the literature. Eye. 2011;25:981-988.
 

33. McAllister, IL. Central retinal vein occlusion: a review. Clinical and Experimental Ophthalmology. 2012;40:48-58.
 

34. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

35. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

36. Figueroa MS, Contreras I. Potential Anti-VEGF Therapies for CRVO. Drugs. 2012;72(16):2063-2071.
 

37. Ehlers JP, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

38. Ehlers JP, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology.
 

39. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

40. Remington, Lee Ann. Clinical Anatomy of the Visual System, Second Edition. Elsevier Inc., 2005. Print.
 

41. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

42. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

43. McAllister, IL. Central retinal vein occlusion: a review. Clinical and Experimental Ophthalmology. 2012;40:48-58.
 

44. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

45. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

46. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

47. Figueroa MS, Contreras, I. Potential Anti-Vascular Endothelial Growth Factor Therapies for Central Retinal Vein Occlusion. Drugs. 2012;72(16):2063-2071.
 

48. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

49. Laouri M, Chen E, Looman M, Gallagher M. The burden of disease of retinal vein occlusion: review of the literature. Eye. 2011;25:981-988.
 

50. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

51. Laouri M, Chen E, Looman M, Gallagher M. The burden of disease of retinal vein occlusion: review of the literature. Eye. 2011;25:981-988.
 

52. Laouri M, Chen E, Looman M, Gallagher M. The burden of disease of retinal vein occlusion: review of the literature. Eye. 2011;25:981-988.
 

53. Rogers. The Prevalence of RVO: Pooled Data from Population Studies from the US, Europe, Asia and Australia. Ophthalmology. Feb 2010;117(2):313-319.e1.
 

54. Rogers. The Prevalence of RVO: Pooled Data from Population Studies from the US, Europe, Asia and Australia. Ophthalmology. Feb 2010;117(2):313-319.e1.
 

55. Rogers. The Prevalence of RVO: Pooled Data from Population Studies from the US, Europe, Asia and Australia. Ophthalmology. Feb 2010;117(2):313-319.e1.
 

56. Stem MS, Talwar N, Comer GM, et al. A Longitudinal Analysis of Risk Factors Associated with Central Retinal Vein Occlusion. Ophthalmology. 2013;120(2):362-370.
 

57. Stem MS, Talwar N, Comer GM, et al. A Longitudinal Analysis of Risk Factors Associated with Central Retinal Vein Occlusion. Ophthalmology. 2013;120(2):362-370.
 

58. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

59. Stem MS, Talwar N, Comer GM, et al. A Longitudinal Analysis of Risk Factors Associated with Central Retinal Vein Occlusion. Ophthalmology. 2013;120(2):362-370.
 

60. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

61. Kiire CA, Chong NV. Managing retinal vein occlusion. BMJ. 2012;344(e499):1-16.
 

62. Kiire CA, Chong NV. Managing retinal vein occlusion. BMJ. 2012;344(e499):1-16.
 

63. Kiire CA, Chong NV. Managing retinal vein occlusion. BMJ. 2012;344(e499):1-16.
 

64. Spina C, Benedetto U, Parodi MB, et al. Practical Management of Retinal Vein Occlusions. Ophthalmol Ther. 2012;1(3):1-10.
 

65. Kiire CA, Chong NV. Managing retinal vein occlusion. BMJ. 2012;344(e499):1-16.
 

66. Kiire CA, Chong NV. Managing retinal vein occlusion. BMJ. 2012;344(e499):1-16.
 

67. Adv Ther (2011) 28(1):28-39.
 

68. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

69. Kiire CA, Chong NV. Managing retinal vein occlusion. BMJ. 2012;344(e499):1-16.
 

70. Kiire CA, Chong NV. Managing retinal vein occlusion. BMJ. 2012;344(e499):1-16.
 

71. “Fluorescein angiography.” MedlinePlus. U.S. National Library of Medicine, 15 Aug 2014. Web. 5 Sept 2014. http://www.nlm.nih.gov/medlineplus/ency/article/003846.htm
 

72. Kiire CA, Chong NV. Managing retinal vein occlusion. BMJ. 2012;344(e499):1-16.
 

73. Kiire CA, Chong NV. Managing retinal vein occlusion. BMJ. 2012;344(e499):1-16.
 

74. “Fluorescein angiography.” MedlinePlus. U.S. National Library of Medicine, 15 Aug 2014. Web. 5 Sept 2014. http://www.nlm.nih.gov/medlineplus/ency/article/003846.htm
 

75. Aref A, Scott IU. Management of Macular Edema Secondary to Branch Retinal Vein Occlusion: an Evidence-Based Update. Adv Ther. 2011;28(1):28-39.
 

76. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

77. Kiire CA, Chong NV. Managing retinal vein occlusion. BMJ. 2012;344(e499):1-16.
 

78. “Optical coherence tomography.” Texas Heart Institute. Web. 8 Sept 2014. http://www.texasheartinstitute.org/HIC/Topics/Diag/diag_oct.cfm
 

79. Spina C, Benedetto U, Parodi MB, et al. Practical Management of Retinal Vein Occlusions. Ophthalmol Ther. 2012;1(3):1-10.
 

80. Spina C, Benedetto U, Parodi MB, et al. Practical Management of Retinal Vein Occlusions. Ophthalmol Ther. 2012;1(3):1-10.
 

81. Spina C, Benedetto U, Parodi MB, et al. Practical Management of Retinal Vein Occlusions. Ophthalmol Ther. 2012;1(3):1-10.
 

82. Figueroa, Contreras. “Potential Anti-VEGF Therapies for CRVO.” Drugs. 2012.
 

83. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

84. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

85. Central retinal vein occlusion: a review. McAllister, L Ian. 2012. Clinical and Experimental Ophthalmology.
 

86. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

87. Figueroa MS, Contreras, I. “Potential Anti-Vascular Endothelial Growth Factor Therapies for Central Retinal Vein Occlusion.” Drugs. 2012;72(16):2063-2071.
 

88. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

89. Kiire CA, Chong NV. Managing retinal vein occlusion. BMJ. 2012;344(e499):1-16.
 

90. McAllister IL. Central retinal vein occlusion: a review. Clinical and Experimental Ophthalmology. 2012;40:48–58.
 

91. Figueroa MS, Contreras, I. “Potential Anti-Vascular Endothelial Growth Factor Therapies for Central Retinal Vein Occlusion.” Drugs. 2012;72(16):2063-2071.
 

92. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

93. Laouri M, Chen E, Looman M, et al. The burden of disease of retinal vein occlusion: review of the literature. Eye. 2011; 25, 981–988.
 

94. Kiire CA, Chong NV. Managing retinal vein occlusion. BMJ. 2012;344(e499):1-16.
 

95. Kiire CA, Chong NV. Managing retinal vein occlusion. BMJ. 2012;344(e499):1-16.
 

96. Campochiaro PA, Bhisitkul RB, Shapiro H, et al. Vascular Endothelial Growth Factor Promotes Progressive Retinal Nonperfusion in Patients with Retinal Vein Occlusion. Ophthalmology. April 2013;120(4):795-802.
 

97. Kiire CA, Chong NV. Managing retinal vein occlusion. BMJ. 2012;344(e499):1-16.
 

98. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

100. Regeneron Announces FDA Approval of EYLEA® (aflibercept) Injection For Macular Edema Following Central Retinal Vein Occlusion. Regeneron Pharmaceuticals, Inc. 21 Sept 2012. [Press Release] Accessed 10 Sept 2014. http://investor.regeneron.com/releasedetail.cfm?ReleaseID=708835
 

101. “EYLEA® (aflibercept) Injection Approved in Europe for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion” [press release.] Regeneron. Aug 29, 2013. Accessed Aug 29, 2013, http://investor.regeneron.com/releaseDetail.cfm?ReleaseID=787761.
 

103. Lucentis prescribing information 2014. Genentech, Inc. Accessed 9 Sept 2014. http://www.gene.com/download/pdf/lucentis_prescribing.pdf
 

104. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for Macular Edema following Central Retinal Vein Occlusion Six-Month Primary End Point Results of a Phase III Study. Ophthalmology. June 2010;11 (6):1124-1133.e1.
 

105. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for Macular Edema following Central Retinal Vein Occlusion Six-Month Primary End Point Results of a Phase III Study. Ophthalmology. June 2010;11 (6):1124-1133.e1.
 

106. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118:2041–9.
 

107. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118:2041–9.
 

108. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118:2041–9.
 

109. Karagiannis DA, Karampelas MD, Soumplis VM, et al. Recurrence of macular edema in retinal vein occlusions after treatment with intravitreal ranibizumab (Lucentis). Can J Ophthalmol. Dec 2011;46(6):486-490.
 

110. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

111. Kiire CA, Chong NV. Managing retinal vein occlusion. BMJ. 2012;344(e499):1-16.
 

112. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for Macular Edema following Central Retinal Vein Occlusion Six-Month Primary End Point Results of a Phase III Study. Ophthalmology. June 2010;11 (6):1124-1133.e1.
 

113. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118:2041–9.
 

114. . “Information for Patients With Macular Edema Following CRVO.” Eylea. Regeneron Pharmaceuticals, Inc., July 2013. Web: 10 Sept 2014. http://www.eylea.us/index.php?id=53
 

115. Boyer D, Heier J, Brown DM, et al. Vascular Endothelial Growth Factor Trap-Eye for Macular Edema Secondary to Central Retinal Vein Occlusion Six-Month Results of the Phase 3 COPERNICUS Study. Ophthalmology. May 2012;119(5):1024-1032.
 

116. Boyer D, Heier J, Brown DM, et al. Vascular Endothelial Growth Factor Trap-Eye for Macular Edema Secondary to Central Retinal Vein Occlusion Six-Month Results of the Phase 3 COPERNICUS Study. Ophthalmology. May 2012;119(5):1024-1032.
 

117. Holz FG, Roider J, Ogura Y, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. J Ophthalmol. 2013;97:278–284.
 

118. Boyer D, Heier J, Brown DM, et al. Vascular Endothelial Growth Factor Trap-Eye for Macular Edema Secondary to Central Retinal Vein Occlusion Six-Month Results of the Phase 3 COPERNICUS Study. Ophthalmology. May 2012;119(5):1024-1032.
 

119. Holz FG, Roider J, Ogura Y, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. J Ophthalmol. 2013;97:278–284.
 

120. Boyer D, Heier J, Brown DM, et al. Vascular Endothelial Growth Factor Trap-Eye for Macular Edema Secondary to Central Retinal Vein Occlusion Six-Month Results of the Phase 3 COPERNICUS Study. Ophthalmology. May 2012;119(5):1024-1032.
 

121. Holz FG, Roider J, Ogura Y, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. J Ophthalmol. 2013;97:278–284.
 

122. Boyer D, Heier J, Brown DM, et al. Vascular Endothelial Growth Factor Trap-Eye for Macular Edema Secondary to Central Retinal Vein Occlusion Six-Month Results of the Phase 3 COPERNICUS Study. Ophthalmology. May 2012;119(5):1024-1032.
 

123. Holz FG, Roider J, Ogura Y, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. J Ophthalmol. 2013;97:278–284.
 

124. Brown DM, Heier JS, Clark WL. Intravitreal Aflibercept Injection for Macular Edema Secondary to Central Retinal Vein Occlusion: 1-Year Results From the Phase 3 COPERNICUS Study. American Journal of Ophthalmology. 2013.
 

125. Brown DM, Heier JS, Clark WL. Intravitreal Aflibercept Injection for Macular Edema Secondary to Central Retinal Vein Occlusion: 1-Year Results From the Phase 3 COPERNICUS Study. American Journal of Ophthalmology. 2013.
 

126. Brown DM, Heier JS, Clark WL. Intravitreal Aflibercept Injection for Macular Edema Secondary to Central Retinal Vein Occlusion: 1-Year Results From the Phase 3 COPERNICUS Study. American Journal of Ophthalmology. 2013.
 

127. Ogura Y, Korobelnik JF, Roider J, et al. Eighteen-Month Results of the GALILEO Study Evaluating Intravitreal Aflibercept Injection (IAI) for Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO). Presented at ARVO 2013 Annual Meeting Abstracts (Seattle, WA). May 6-9, 2013. Abstract # 4516.
 

128. Brown DM, Heier JS, Clark WL. Intravitreal Aflibercept Injection for Macular Edema Secondary to Central Retinal Vein Occlusion: 1-Year Results From the Phase 3 COPERNICUS Study. American Journal of Ophthalmology. 2013.
 

129. Ogura Y, Korobelnik JF, Roider J, et al. Eighteen-Month Results of the GALILEO Study Evaluating Intravitreal Aflibercept Injection (IAI) for Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO). Presented at ARVO 2013 Annual Meeting Abstracts (Seattle, WA). May 6-9, 2013. Abstract # 4516.
 

130. Brown DM, Heier JS, Clark WL. Intravitreal Aflibercept Injection for Macular Edema Secondary to Central Retinal Vein Occlusion: 1-Year Results From the Phase 3 COPERNICUS Study. American Journal of Ophthalmology. 2013.
 

131. Ogura Y, Korobelnik JF, Roider J, et al. Eighteen-Month Results of the GALILEO Study Evaluating Intravitreal Aflibercept Injection (IAI) for Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO). Presented at ARVO 2013 Annual Meeting Abstracts (Seattle, WA). May 6-9, 2013. Abstract # 4516.
 

132. Ogura Y, Korobelnik JF, Roider J, et al. Eighteen-Month Results of the GALILEO Study Evaluating Intravitreal Aflibercept Injection (IAI) for Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO). Presented at ARVO 2013 Annual Meeting Abstracts (Seattle, WA). May 6-9, 2013. Abstract #4516.
 

133. Brown DM, Heier JS, Clark WL. Intravitreal Aflibercept Injection for Macular Edema Secondary to Central Retinal Vein Occlusion: 1-Year Results From the Phase 3 COPERNICUS Study. American Journal of Ophthalmology. 2013.
 

134. The burden of disease of retinal vein occlusion: review of the literature. Laouri M, Chen E, Looman M, Gallagher M. Eye. 2011
 

135. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

136. Kiire CA, Chong NV. Managing retinal vein occlusion. BMJ. 2012;344(e499):1-16.
 

137. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

138. Scott I. Management of Macular Edema Associated With Retinal Vein Occlusion. Arch Ophthalmol. Oct 2012;130(10).
 

139. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

140. ARCH OPHTHALMOL/VOL 130 (NO. 10), OCT 2012
 

141. McAllister IL. Central retinal vein occlusion: a review. Clinical and Experimental Ophthalmology. 2012;40:48–58.
 

142. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

143. Laouri M, Chen E, Looman M, Gallagher M. The burden of disease of retinal vein occlusion: review of the literature. Eye. 2011;25:981-988.
 

144. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

145. Kiire CA, Chong NV. Managing retinal vein occlusion. BMJ. 2012;344(e499):1-16.
 

146. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

147. Bhatnagar P, Schiff WM, Barile GR. Diabetic vitrectomy: the influence of lens status upon surgical outcomes. Curr Opin Ophthalmol. May 2008; 19(3):243-7. .
 

148. McAllister, IL. Central retinal vein occlusion: a review. Clinical and Experimental Ophthalmology. 2012;40:48-58.
 

149. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

150. Kiire CA, Chong NV. Managing retinal vein occlusion. BMJ. 2012;344(e499):1-16.
 

151. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

152. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

153. McAllister IL. Central retinal vein occlusion: a review. Clinical and Experimental Ophthalmology. 2012;40:48–58.
 

154. Figueroa MS, Contreras I. Potential Anti-VEGF Therapies for CRVO. Drugs. 2012;72(16):2063-2071.
 

155. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

156. (Central retinal vein occlusion: a review. McAllister, L Ian. 2012. Clinical and Experimental Ophthalmology.)
 

157. Ehlers J, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology. 2011;56(4):281-295.
 

158. Stem MS, Talwar N, Comer GM, et al. A Longitudinal Analysis of Risk Factors Associated with Central Retinal Vein Occlusion. Ophthalmology. 2013;120(2):362-370.

 

160. EYLEA® (aflibercept) Injection Approved For The Treatment of Macular Edema Following Central Retinal Vein Occlusion In Japan. Regeneron Pharmaceuticals, Inc. 22 Nov 2013. [Press Release] Accessed 10 Sept 2014.

 

161. FDA Approves Lucentis® (Ranibizumab Injection) for the Treatment of Macular Edema Following Retinal Vein Occlusion. Genentech. 22 June 2010. [Press Release] Accessed 10 Sept 2014. http://www.gene.com/media/press-releases/12827/2010-06-22/fda-approves-lucentis-ranibizumab-inject